IDYA
IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA\'s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.
IDEAYA Biosciences, Inc. (IDYA) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Value (C).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C (2.4) | C+ (2.5) | C+ (2.8) | B- (3.1) | C+ (2.6) | C+ (2.7) |
| 2026-11-05 | C (2.5) | C+ (2.5) | C+ (2.6) | B (3.2) | C+ (2.7) | C+ (2.7) |
| 2026-10-29 | B- (2.9) | B+ (3.5) | B- (2.9) | B (3.2) | C+ (2.7) | B- (3.0) |
| 2026-10-22 | B- (2.9) | B (3.5) | B- (2.9) | B (3.2) | C+ (2.6) | B- (3.0) |
| 2026-10-15 | B- (2.9) | B+ (3.5) | B- (2.9) | B- (3.0) | C+ (2.6) | B- (3.0) |